{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:01:49Z","timestamp":1770282109518,"version":"3.49.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The long-term use of calcineurin inhibitors (CNIs) after liver transplantation (LT) is associated with nephrotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Five-year follow-up data were retrieved from the randomized controlled multicenter SiLVER trial. Standard CNI-based mammalian target of rapamycin-free immunosuppression (group A, n = 264) was compared with a 50% reduction of CNI and introduction of the mammalian target of rapamycin inhibitor Sirolimus (SIR) within 4\u20136 weeks after LT (group B, n = 261).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Median MELD at LT was low with 10 (7\u201315) (group A) and 11 (8\u201315) (group B) in the intention-to-treat approach. CNI dose and CNI trough were reduced by 20% and 8% (group A) versus 55% and 56% (group B) at 3 months posttransplantation. Renal function was preserved at 3 months after LT in the SIR arm (estimated glomerular filtration rate 74 [57\u201395] versus 67 [55\u201385] mL\/min\/1.73m2 <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004) but was similarly impaired thereafter compared with group A. The per protocol analysis identified LT recipients in group B with concomitant early CNI minimization and SIR treatment \u2265 year 1 with significantly superior estimated glomerular filtration rate and lowest rate of chronic kidney disease (\u2265stage 3) from year 1 onwards until study end. Competing risk factors for renal disease (arterial hypertension, fat metabolism disorder, and hyperglycemia) were not associated with worse kidney function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Prevention of CNI nephrotoxicity by SIR-based early CNI minimization protects renal function only short-term after LT in the intention-to-treat analysis of this low MELD cohort. Yet, selected LT recipients compliant with early CNI minimization and SIR maintenance achieved better long-term renal outcomes compared with real-world practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002980","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:20:57Z","timestamp":1570029657000},"page":"1003-1018","source":"Crossref","is-referenced-by-count":19,"title":["Randomized Sirolimus-based Early Calcineurin Inhibitor Reduction in Liver Transplantation: Impact on Renal Function"],"prefix":"10.1097","volume":"104","author":[{"given":"Bettina M.","family":"Buchholz","sequence":"first","affiliation":[{"name":"Liver Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Liver Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, United Kingdom."},{"name":"Institute of Immunology and Immunotherapy, National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Centre (BRC), University of Birmingham, Birmingham, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas A.","family":"Schnitzbauer","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, Frankfurt University Hospital, Goethe-University Frankfurt, Frankfurt\/Main, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nightingale","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine (ITM), University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.","family":"Schlitt","sequence":"additional","affiliation":[{"name":"Department of Surgery and Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward K.","family":"Geissler","sequence":"additional","affiliation":[{"name":"Department of Surgery and Section of Experimental Surgery, University Hospital Regensburg, Regensburg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darius F.","family":"Mirza","sequence":"additional","affiliation":[{"name":"Liver Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, United Kingdom."},{"name":"Institute of Immunology and Immunotherapy, National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Centre (BRC), University of Birmingham, Birmingham, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the International SiLVER study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00000658-199009000-00008","article-title":"Liver, kidney, and thoracic organ transplantation under FK 506.","volume":"212","author":"Todo","year":"1990","journal-title":"Ann Surg"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(79)92440-1","article-title":"Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.","volume":"2","author":"Calne","year":"1979","journal-title":"Lancet"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trre.2013.04.003","article-title":"The impact of calcineurin inhibitors on graft survival.","volume":"27","author":"Rush","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine.","volume":"321","author":"Kahan","year":"1989","journal-title":"N Engl J Med"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00007890-198803000-00015","article-title":"An analysis of cyclosporine efficacy and toxicity after liver transplantation.","volume":"45","author":"O\u2019Grady","year":"1988","journal-title":"Transplantation"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ.","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40 years later, can\u2019t live without.","volume":"191","author":"Azzi","year":"2013","journal-title":"J Immunol"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-6143.2008.02493.x","article-title":"Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the \u2018respect\u2019 study.","volume":"9","author":"Neuberger","year":"2009","journal-title":"Am J Transplant"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation\u2013PROTECT.","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.14212","article-title":"Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial.","volume":"17","author":"Saliba","year":"2017","journal-title":"Am J Transplant"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/lt.23658","article-title":"Calcineurin inhibitor-free mycophenolate mofetil\/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transpl"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399400001769","article-title":"Molecular targets for existing and novel immunosuppressive drugs.","volume":"2","author":"Stepkowski","year":"2000","journal-title":"Expert Rev Mol Med"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","article-title":"Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.","volume":"2","author":"Morales","year":"2002","journal-title":"Am J Transplant"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1600-6143.2011.03919.x","article-title":"Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial.","volume":"12","author":"Abdelmalek","year":"2012","journal-title":"Am J Transplant"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial.","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/TP.0000000000001255","article-title":"The authors\u2019 reply.","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2407-10-190","article-title":"A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.","volume":"10","author":"Schnitzbauer","year":"2010","journal-title":"BMC Cancer"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R19-20231002","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Stevens","year":"2013","journal-title":"Kidney International Supplements"},{"key":"R20-20231002","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R21-20231002","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/TP.0b013e3181a23cb2","article-title":"The challenge of achieving target drug concentrations in clinical trials: experience from the symphony study.","volume":"87","author":"Ekberg","year":"2009","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"R22-20231002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1463-1326.2011.01506.x","article-title":"Optimal management of type 2 diabetes: the evidence.","volume":"14","author":"Colagiuri","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R23-20231002","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","article-title":"Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.","volume":"14","author":"Esposito","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R24-20231002","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","article-title":"Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis.","volume":"12","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2012","journal-title":"Am J Transplant"},{"key":"R25-20231002","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1681\/ASN.V1251059","article-title":"Pharmacokinetic interactions augment toxicities of sirolimus\/cyclosporine combinations.","volume":"12","author":"Podder","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R26-20231002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The rapamune US study group.","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"R27-20231002","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2014.03.034","article-title":"Chronic kidney disease and associated mortality after liver transplantation\u2013a time-dependent analysis using measured glomerular filtration rate.","volume":"61","author":"Allen","year":"2014","journal-title":"J Hepatol"},{"key":"R28-20231002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease.","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"R29-20231002","doi-asserted-by":"crossref","first-page":"e64089","DOI":"10.1371\/journal.pone.0064089","article-title":"Role of MELD score and serum creatinine as prognostic tools for the development of acute kidney injury after liver transplantation.","volume":"8","author":"Romano","year":"2013","journal-title":"Plos One"},{"key":"R30-20231002","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"key":"R31-20231002","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1097\/TP.0000000000000779","article-title":"Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment: results of a pilot study (PATRON07).","volume":"99","author":"Schnitzbauer","year":"2015","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"R32-20231002","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/2047-1440-2-S1-S3","article-title":"Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?","volume":"2","author":"Gatault","year":"2013","journal-title":"Transplant Res"},{"key":"R33-20231002","doi-asserted-by":"crossref","first-page":"E316","DOI":"10.1111\/j.1399-0012.2012.01650.x","article-title":"Modifiable patient factors are associated with the late decline in renal function following liver transplantation.","volume":"26","author":"Leithead","year":"2012","journal-title":"Clin Transplant"},{"key":"R34-20231002","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/ajt.13765","article-title":"Protecting the kidney in liver transplant recipients: practice-based recommendations from the american society of transplantation liver and intestine community of practice.","volume":"16","author":"Levitsky","year":"2016","journal-title":"Am J Transplant"},{"key":"R35-20231002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12882-019-1274-5","article-title":"Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population.","volume":"20","author":"Singh","year":"2019","journal-title":"BMC Nephrol"},{"issue":"suppl_1","key":"R36-20231002","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/rheumatology\/kex432","article-title":"Cardiac and renal protective effects of urate-lowering therapy.","volume":"57","author":"Richette","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R37-20231002","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/ctr.12744","article-title":"Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.","volume":"30","author":"Sterneck","year":"2016","journal-title":"Clin Transplant"},{"key":"R38-20231002","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2013.04.003","article-title":"Immunosuppression minimization vs. complete drug withdrawal in liver transplantation.","volume":"59","author":"Londo\u00f1o","year":"2013","journal-title":"J Hepatol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:23:12Z","timestamp":1696224192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002980","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}